A clinical Trial to Study the Effects of Hydroxychloroquine, Ciclesonide and Ivermectin in treatment of moderate COVID-19 illness

EFFICACY OF HYDROXYCHLOROQUINE, CICLESONIDE AND IVERMECTIN IN TREATMENT OF MODERATE COVID-19 ILLNESS: AN OPEN-LABEL RANDOMISED CONTROLLED STUDY - EHYCIVER-COVID

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2020/04/024948

Enrollment

120

Registered

2020-04-30

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere Health Condition 2: B338- Other specified viral diseases

Interventions

Intervention1: Hydroxychloroquine: 400 mg bid Day1 followed by 200 mg bid on Days 2 to 7 Intervention2: Ciclesonide: 200 mcg bid for 7 days Intervention3: Ivermectin: 12 mg OD for 7 days Control Inter

Eligibility

Inclusion criteria

Inclusion criteria: • Adult patients (>=18years) suffering from Covid-19. A positive throat swab (by real time PCR) obtained from a patient suspected to be Covid-19 or from a contact (or HCW) of Covid-19 patient will be considered to be a Covid-19 case. • Presence of moderate Covid-19 disease (10) as defined by presence of pneumonia (clinical and radiological signs) with respiratory rate between 15 to 30/minute and/or SpO2 90%-94% on room air.

Exclusion criteria

Exclusion criteria: • Patients with renal or hepatic dysfunction (Serum creatinine > 1.5 mg/dL and serum transaminase levels >120 U/L) • Patients with clinical heart failure/known CAD • Known cases of neoplasms or immunodeficiency syndromes • Patients who are on chemotherapy, immunosuppressive agents, steroids or antiviral agents, or have received in the preceding 4 weeks • Pregnant and lactating patients • Uncooperative patients (in the opinion of the investigator, if it is difficult to ensure patient cooperation during the study)

Design outcomes

Primary

Measure	Time frame
Proportion of patients having virologic cure on Day 6 in each of the groupsTimepoint: Day 6 of treatment initiation	—

Secondary

Measure	Time frame
o Proportion of patients having resolution of symptoms/signs on Day 7 and Day 14, in each of the groups o The individual proportion of the aforementioned rescue criteria in each of the groups. o Side-effects noted in each of the group Timepoint: Day 7 and Day 14	—

Countries

India

Contacts

Public ContactAnupam Prakash

LADY HARDINGE MEDICAL COLLEGE

prakashanupam@hotmail.com8588885305

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026